Related references
Note: Only part of the references are listed.Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
Simon Schallenberg et al.
BMC CANCER (2020)
Precision medicine for ovarian clear cell carcinoma based on gene alterations
Takafumi Kuroda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Ronja Morsch et al.
BMC CANCER (2020)
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Sangeeta Goswami et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
Michael Rose et al.
ONCOGENE (2020)
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines
Katharina Ehrenhoefer-Woelfer et al.
SCIENTIFIC REPORTS (2019)
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma
Takafumi Kuroda et al.
GYNECOLOGIC ONCOLOGY (2019)
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
Sumati Gupta et al.
MOLECULAR CANCER THERAPEUTICS (2019)
ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
Joseph J. Caumanns et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Stefan Garczyk et al.
PLOS ONE (2018)
Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes
Nazar Mashtalir et al.
CELL (2018)
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
Brittany C. Michel et al.
NATURE CELL BIOLOGY (2018)
Synthetic lethality and cancer
Nigel J. O'Neil et al.
NATURE REVIEWS GENETICS (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Jian Chen et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2016)
ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma
Jianhong Li et al.
HUMAN PATHOLOGY (2016)
Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract
Abbas Agaimy et al.
VIRCHOWS ARCHIV (2016)
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T. Williamson et al.
NATURE COMMUNICATIONS (2016)
Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup
Philipp H. Baldia et al.
ONCOTARGET (2016)
Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches
Jeremy W. Martin et al.
ARAB JOURNAL OF UROLOGY (2016)
Potential therapeutic targets in ARID1A-mutated cancers
Benjamin G. Bitler et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
Anna Fischbach et al.
HISTOPATHOLOGY (2015)
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling
Ronald L. Chandler et al.
NATURE COMMUNICATIONS (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
Claudio Luchini et al.
ONCOTARGET (2015)
Epigenetic treatment of solid tumours: a review of clinical trials
Clara Nervi et al.
CLINICAL EPIGENETICS (2015)
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Margaret A. Knowles et al.
NATURE REVIEWS CANCER (2015)
SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability
Reiko Watanabe et al.
CANCER RESEARCH (2014)
Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours
Michael Rose et al.
CARCINOGENESIS (2014)
ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas
Ghassan Allo et al.
MODERN PATHOLOGY (2014)
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
Tjalling Bosse et al.
MODERN PATHOLOGY (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?
Jennifer N. Wu et al.
CANCER DISCOVERY (2013)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers
Bin Guan et al.
CANCER RESEARCH (2011)
Massive Parallel DNA Pyrosequencing Analysis of the Tumor Suppressor BRG1/SMARCA4 in Lung Primary Tumors
Salvador Rodriguez-Nieto et al.
HUMAN MUTATION (2011)
The plasmacytoid carcinoma of the bladder-rare variant of aggressive urothelial carcinoma
Bastian Keck et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
The human urothelium consists of multiple clonal units, each maintained by a stem cell
Nadine T. Gaisa et al.
JOURNAL OF PATHOLOGY (2011)
Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer
Nadine T. Gaisa et al.
VIRCHOWS ARCHIV (2011)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The SWI/SNF complex and cancer
D. Reisman et al.
ONCOGENE (2009)
Nonurothelial cancer of the bladder
Hassan Abol-Enein et al.
UROLOGY (2007)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Racial variation in the incidence of squamous cell carcinoma of the bladder in the United States
MP Porter et al.
JOURNAL OF UROLOGY (2002)
Epidemiology and etiology of premalignant and malignant urothelial changes
SM Cohen et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2000)
Share Paper
